Literatur
- 1
Nagao K. for the SOS-KANTO study group .
Cardiopulmonary resuscitation by bystanders with chest compression only (SOS-KANTO):
an observational study.
Lancet.
2007;
369
920-926
- 2
Boden W E, O’Rourke R A, Teo K K. et al .
Optimal medical therapy with or without PCI for stable coronary disease.
N Engl J Med.
2007;
356
1503-1516
- 3
Eisenstein E L, Anstrom K J, Kong D F. et al .
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
JAMA.
2007;
297
159-168
- 4
Fuster V, Ryden L E, Cannom D S. et al .
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive
summary: a report of the American College of Cardiology/American Heart Association
Task Force on practice guidelines and the European Society of Cardiology Committee
for Practice Guidelines.
Eur Heart J.
2006;
27
1979-2030
- 5
Gheorghiade M. et al .
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients
hospitalized for heart failure: the EVEREST Clinical Status Trials.
JAMA.
2007;
297
1332-1343
- 6
Holmes D R, Teirstein P, Satler L. et al .
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within
bare-metal stents: the SISR randomized trial.
JAMA.
2006;
295
1264-1273
- 7
Kastrati A, Mehilli J, Pache J. et al .
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
N Engl J Med.
2007;
356
1030-1039
- 8
Konstam M A, Gheorghiade M, Burnett J C. et al .
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the
EVEREST Outcome Trial.
JAMA.
2007;
297
1319-1331
- 9
Lagerqvist B, James S K, Stenestrand U. et al .
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
N Engl J Med.
2007;
356
1009-1019
- 10
Mauri L, Hsieh W H, Massaro J M. et al .
Stent thrombosis in randomized clinical trials of drug-eluting stents.
N Engl J Med.
2007;
356
1020-1029
- 11
Mebazaa A, Nieminen M S, Packer M. et al .
Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The
SURVIVE Randomized Trial.
JAMA.
2007;
297
1883-1891
- 12
Morice M C, Colombo A, Meier B. et al .
Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY
trial: a randomized controlled trial.
JAMA.
2006;
295
895-904
- 13
Oral H. et al .
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
N Engl J Med.
2006;
354
934-941
- 14
Scheller B, Hehrlein C, Bocksch W. et al .
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.
N Engl J Med.
2006;
355
2113-2124
- 15
Stone G W, Ellis S G, O’Shaughnessy C D. et al .
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within
bare-metal stents: the TAXUS V ISR randomized trial.
JAMA.
2006;
295
1253-1263
- 16
Stone G W, Moses J W. et al .
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
N Engl J Med.
2007;
356
998-1008
Prof. Dr. med. Erland Erdmann
Prof. Dr. med. Uta C. Hoppe
Klinik III für Innere Medizin, Universität zu Köln
Kerpener Straße 62
50937 Köln
Phone: 0221/4784503
Fax: 0221/4786275
